Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response
- 10 December 2009
- journal article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 17 (4), 469-477
- https://doi.org/10.1038/gt.2009.150
Abstract
Fusion of dendritic cells and tumor cells (FCs) constitutes a promising tool for generating an antitumor response because of their capacity to present tumor antigens and provide appropriate costimulatory signals. CD40–CD40L interaction has an important role in the maturation and survival of dendritic cells and provides critical help for T-cell priming. In this study, we sought to improve the effectiveness of FC vaccines in a murine model of B-cell lymphoma by engineering FCs to express CD40L by means of an adenovirus encoding CD40L (Adv-CD40L). Before transduction with Adv-CD40L, no CD40L expression was detected in FCs, DCs or tumor cells. The surface expression of CD40L in FC transduced with Adv-CD40L (FC-CD40L) ranged between 50 and 60%. FC-CD40L showed an enhanced expression of CD80, CD86, CD54 and MHC class II molecules and elicited a strong in vitro immune response in a syngeneic mixed lymphocyte reaction. Furthermore, FC-CD40L showed enhanced migration to secondary lymphoid organs. Splenocytes from mice treated with FC-CD40L had a dramatic increase in the production of IL-17, IL-6 and IFN-γ, compared with controls. Treatment with the FC-CD40L vaccine induced regression of established tumors and increased survival. Our data demonstrate that FC transduced with Adv-CD40L enhances the antitumor effect of FC vaccines in a murine lymphoma model and this is associated with an increased Th17-type immune response.Keywords
This publication has 44 references indexed in Scilit:
- Type 17 CD8+ T cells display enhanced antitumor immunityBlood, 2009
- Cytokine mediators of Th17 functionEuropean Journal of Immunology, 2009
- CD40–CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4 + T cellsProceedings of the National Academy of Sciences, 2009
- Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myelomaBlood, 2008
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Th17 cells in human diseaseImmunological Reviews, 2008
- Dendritic Cell-Tumor Fusion Vaccine Prevents Tumor Growthin VivoBioscience, Biotechnology, and Biochemistry, 2007
- Expanding the effector CD4 T-cell repertoire: the Th17 lineageCurrent Opinion in Immunology, 2006
- DNA fusion gene vaccines against cancer: from the laboratory to the clinicImmunological Reviews, 2004
- Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunityInternational Journal of Cancer, 1998